3P Biopharmaceuticals awards prize for the best Final Degree Project in Pharmacy at the University of Navarra

3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of biological products, recently awarded the best Final Project Degree (FPD) of Pharmacy. The award forms part of an agreement between 3P and the Faculty of Pharmacy at the University of Navarra promoting digital transformation and professional training within the pharmaceutical industry.

[Noáin, Spain, May 31, 2022] 3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of biological products, recently awarded the best Final Project Degree (FPD) of Pharmacy.

The award forms part of an agreement between 3P and the Faculty of Pharmacy at the University of Navarra promoting digital transformation and professional training within the pharmaceutical industry. At the same time, encouraging research in technologies, and the production of new medicines, particularly in biotechnologies.

3P Biopharmaceuticals awards its first prize for the best Final Degree Project in Pharmacy at the University of Navarra

The first winner of the 3P award is Ángela Covo, a Pharmacy degree student, for her experimental work on: “Overcoming T cell dysfunction in the acidic tumor microenvironment.” Ángela successfully achieved a grade of 9.32 and was awarded a prize of €300 and a diploma.

According to the CEO of 3P Biopharmaceuticals, Dámaso Molero, “It is an honor to be able to present the first 3P Biopharmaceuticals Award for the best Final Degree Project. All the graduating students have obtained very high grades and it tells us that we are training future professionals with a technical-scientific profile of the highest level who will add a lot of value to Navarra and the Spanish biopharmaceutical sector.

The agreement with 3P and the Pharmacy Faculty concentrates on new medicine and advanced therapies in R&D, including the development of biological drugs, cell and gene therapy, manufacturing and analytical technology, and dispensing technology. With the intention of manufacturing drugs that are safer and aimed at diseases that, until now, have no cure or with treatments without serious side effects.

In addition to the 3P Final Degree Project award, the collaboration between the two bodies delivers events, courses, seminars, and scientific meetings.

View the full press release here

Related Content

3P Biopharmaceuticals celebrates its 15th anniversary with Juan Carlos Unzué.

3P Biopharmaceuticals, a Navarre company founded in 2007, met with 370 employees in an exciting and joyful event looking back over its 15 years of trajectory.
Read more

3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.

3P Biopharmaceuticals has completed the manufacture of BSG005 biomass planned for its client Biosergen. The client also recently announced Phase II clinical trial of BSG005 against Mucormycosis, otherwise known as the Black Fungus.
Read more

Regional Minister Irujo presents the Navarra Health Cluster

This morning, the Regional Minister for Economic and Business Development, Mikel Irujo, presented the Navarra Health Cluster, seeking to position the region as a European benchmark in personalized medicine, one of the priorities of the S4 Smart Specialisation Strategy. The initiative, which stems from the sector's demand and is led by a driving group, is now open to other companies and entities interested in participating.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.